Introduction {#sec1}
============

Gentamicins are clinically valuable aminoglycoside antibiotics isolated as gentamicin C complex, a mixture of five components ([Figure 1](#fig1){ref-type="fig"}), from the filamentous bacterium *Micromonospora echinospora*. Gentamicins are protein synthesis inhibitors used to combat Gram-negative bacterial infections. They are also being explored in other therapeutic areas ([@bib10; @bib28; @bib3]). However, gentamicins carry a serious risk of kidney damage and hearing loss ([@bib2]) which limits their utility, and it is therefore encouraging that evidence is available that an individual component of the gentamicin mixture may have lower toxicity ([@bib36; @bib24]). This makes the gentamicin biosynthetic pathway an attractive target for reengineering to favor a specific component.

Gentamicins are modified sugars, characteristically containing an unusual aminocyclitol ring (2-deoxystreptamine, 2-DOS \[**1**\]) ([@bib13; @bib34]). The outlines of the gentamicin pathway have been known for some time ([@bib39; @bib40; @bib17; @bib18]), and in the wake of the comprehensive sequencing of aminoglycoside biosynthetic gene clusters ([@bib31; @bib42; @bib19; @bib20; @bib21; @bib14; @bib37; @bib1; @bib12]) rapid progress has been made in identifying the enzymatic steps that lead to the 2-DOS scaffold, and thence to the pseudodisaccharide paromamine (**2**) ([@bib29; @bib41; @bib25; @bib26]) and the pseudotrisaccharide gentamicin A2 (**3**) ([@bib32]) ([Figure 1](#fig1){ref-type="fig"}). This has enabled a sharper focus on those genes likely to govern the later steps of gentamicin biosynthesis.

We ([@bib9]) and others ([@bib16; @bib11; @bib27]) have used specific gene deletions to probe the identity of the enzymes that act on gentamicin X2 (**4**), partitioning this intermediate between a methylated branch that gives rise via G418 (**5**) to gentamicin components C2a, C2, and C1 and an unmethylated branch that gives rise to C1a and C2b ([Figure 1](#fig1){ref-type="fig"}). The cluster contains multiple, mutually homologous genes for methyltransferases, oxidoreductases, and aminotransferases with potential for overlapping substrate specificities, but by combining analysis of specific gene deletions with in vitro reconstitution of the enzymes involved in dehydrogenation/transamination of G418 (**5**) ([@bib9]) it has been possible to deconvolute the specific roles of some of the individual genes in this final stage of the pathway. Also, Liu and colleagues have demonstrated the activity in vitro of GenK, which methylates **4** to produce **5**, and have confirmed that it is a cobalamin-dependent radical *S*-adenosyl-[l]{.smallcaps}-methionine (SAM) enzyme ([@bib23]).

Here we present a similar in vivo and in vitro analysis to define the enzymology of the pathway from the first pseudotrisaccharide **3** to the last common precursor of the gentamicin C complex, gentamicin X2 (**4**). It has already been established that disruption of the gene *genD1*, also known as *gntE* ([@bib42]) or *gtmI* ([@bib21]), by a thiostrepton resistance gene (*tsr*) leads to accumulation of **3** ([Figure 1](#fig1){ref-type="fig"}) ([@bib22]). These authors interpreted their result as meaning that GenD1 catalyzes *N*-methylation of the 3″-amino group in **3**; but several alternative explanations of this result are possible, especially as polar effects on the downstream *genS2* gene were not ruled out. By analysis of the gentamicin-related metabolites accumulated in strains bearing single and multiple specific gene deletions, by following the bioconversion of specific intermediates fed to such mutants, and by reconstituting all of the steps using purified recombinant enzymes, we demonstrate here that in fact the respective (and essential) catalytic contributions of the dehydrogenase GenD2, the pyridoxal phosphate-dependent aminotransferase GenS2, the SAM-dependent *N*-methyltransferase GenN, and the radical SAM-dependent C-methyltransferase GenD1 are as shown in [Figure 1](#fig1){ref-type="fig"}. We also provide evidence for the ability of GenK to act precociously on **3** and gentamicin A (**6**) ([Figure 1](#fig1){ref-type="fig"}) to generate shunt metabolites.

Results {#sec2}
=======

GenD2, GenS2, and GenN Are Essential for Conversion of Gentamicin A2 into Gentamicin A {#sec2.1}
--------------------------------------------------------------------------------------

The gene *genD2* (also known as *gntC* \[[@bib42]\] or *gtmC* \[[@bib21]\]) is a candidate to act on **3** because it is predicted to encode an NAD(P)H-linked dehydrogenase with significant sequence identity to Sis12, KanD2, and TobD2, enzymes catalyzing similar reactions in other aminoglycoside pathways. To investigate the proposed role of the GenD2 dehydrogenase in the specific oxidation of **3** at the C-3″-hydroxyl, this gene was knocked out by targeted in-frame deletion of a 930 bp internal fragment ([Figure S1](#app2){ref-type="sec"}A available online). The mutant was confirmed by PCR and Southern hybridization ([Figure S1](#app2){ref-type="sec"}A). Liquid chromatography/electrospray ionization/high-resolution mass spectrometry (LC-ESI-HRMS) analysis confirmed that fermentation of this mutant produces elevated levels of **3**, but no other gentamicins normally seen in the wild-type ([Figures 2](#fig2){ref-type="fig"}C and [S2](#app2){ref-type="sec"}A). A second new species was also observed, which from LC-ESI-HRMS and tandem mass spectrometry (MS/MS) analysis ([Figure S2](#app2){ref-type="sec"}B) appears to represent a derivative of **3** methylated at the C-6′ position. This species was first detected by [@bib22] as a by-product of their *genD1* disruptant and was named by them gentamicin A2e (**7**; [Figure 1](#fig1){ref-type="fig"}) but not characterized. Complementation of the ΔgenD2 mutant, carried out by using plasmid pWHU184 containing *genD2* under the control of the P*ermE*^∗^ promoter ([Figure S1](#app2){ref-type="sec"}G), restored the production of gentamicin C complex and of various intermediates to wild-type levels ([Figure 2](#fig2){ref-type="fig"}G). Chemical complementation of the ΔgenD2 mutant by feeding **6** also similarly restored production of gentamicin C complex ([Figure S3](#app2){ref-type="sec"}C), confirming the primary role of GenD2 in the section of the pathway between **3** and **6**.

Recent in vivo ([@bib22; @bib11; @bib9]) and in vitro ([@bib23]) work has unequivocally established that methylation at the C-6′ position is normally carried out on **4** by the SAM-dependent methyltransferase GenK. We suspected therefore that the appearance of **7** in our ΔgenD2 mutant was a consequence of the action of GenK in the absence of its normal substrate. To test this, a double mutant deleted in-frame in both *genD2* and *genK* was constructed ([Figure S1](#app2){ref-type="sec"}C). LC-ESI-HRMS analysis confirmed that this mutant accumulated **3** but not **7** ([Figure 2](#fig2){ref-type="fig"}E). Complementation of the ΔgenD2ΔgenK strain with plasmid pWHU67 containing *genK* under the control of the P*ermE*^∗^ promoter ([Figure S1](#app2){ref-type="sec"}K), restored the coproduction of the shunt product **7** ([Figure 2](#fig2){ref-type="fig"}I).

GenS2, the product of the unassigned gene *genS2* (also known as *gntF* \[[@bib42]\] or *gtmD* \[[@bib21]\]) is a plausible candidate to partner GenD2 in amination at C-3″ because it is predicted to encode a pyridoxal phosphate-dependent aminotransferase with significant sequence identity to Sis15, KanS2, and TobS2, enzymes catalyzing similar reactions in other aminoglycoside pathways. Accordingly, this gene was knocked out by targeted in-frame deletion and the mutant was confirmed by PCR and Southern hybridization ([Figure S1](#app2){ref-type="sec"}B). LC-ESI-HRMS analysis confirmed that fermentation of this mutant only produced **3** and **7** ([Figure 2](#fig2){ref-type="fig"}D). Complementation of the ΔgenS2 mutant, carried out by using plasmid pWHU115 containing *genS2* under the control of the P*ermE*^∗^ promoter ([Figure S1](#app2){ref-type="sec"}H), restored the production of gentamicin C complex and of various intermediates to wild-type levels ([Figure 2](#fig2){ref-type="fig"}H). Chemical complementation of the ΔgenS2 mutant by feeding **6** also similarly restored production of gentamicin C complex ([Figure S3](#app2){ref-type="sec"}D), confirming that the *genS2* gene, like *genD2*, is essential and acts exclusively in the section of the pathway between **3** and **6**, consistent with a specific role in partnering GenD2 to accomplish amination at C-3″. Also, the shunt product gentamicin **7** was not present in a ΔgenS2ΔgenK double mutant ([Figures 2](#fig2){ref-type="fig"}F and [S1](#app2){ref-type="sec"}D) but its appearance was restored by complementation in *trans* by constitutive expression of *genK* ([Figures 2](#fig2){ref-type="fig"}J and [S1](#app2){ref-type="sec"}L). The presumed intermediate in amination at C-3″ is 3″-dehydro-3″-oxo-gentamicin A2 (DOA2 \[**8**\]; [Figure 1](#fig1){ref-type="fig"}), and this was not detected in the ΔgenS2 or ΔgenS2ΔgenK mutants. Either the compound is unstable, or the GenD2-catalyzed oxidation does not proceed if the ketone product is not continuously removed (see below).

The third and final step between **3** and the known intermediate **6** involves *N*-methylation of the newly introduced 3″-amino group in the garosamine ring ([Figure 1](#fig1){ref-type="fig"}). Of the several predicted methyltransferase genes in the gentamicin gene cluster, *genN* (GI: 85814038; [@bib1]) is an attractive candidate for this role. It is predicted to encode a conventional SAM-dependent methyltransferase, and its closest known homolog (90% sequence identity) is Sis30 in the cluster for sisomicin (\[**19**\]; [@bib12]), a closely related aminoglycoside which requires a similar *N*-methylation ([Supplemental Experimental Procedures](#app2){ref-type="sec"}). The gene clusters for the aminoglycosides kanamycin (**11**) and tobramycin (**12**), which do not contain a 3″-*N*-methyl group ([Supplemental Experimental Procedures](#app2){ref-type="sec"}), contain no gene homologous to GenN.

GenN was knocked out by targeted in-frame deletion of a 933 bp internal fragment ([Figure S1](#app2){ref-type="sec"}E). LC-ESI-HRMS analysis revealed that fermentation of this mutant produced **3** and **7** ([Figure 2](#fig2){ref-type="fig"}L), together with small amounts of a compound with the predicted mass of 3″-dehydro-3″-amino-gentamicin A2 (DAA2 \[**9**\]; [Figures 1](#fig1){ref-type="fig"} and [S2](#app2){ref-type="sec"}C), but none of the gentamicin C components was detected. Trace amounts of demethylgentamicin C1, demethylgentamicin C2, and demethylgentamicin C1a were observed. The fragmentation profiles of these demethylgentamicins indicate that they lack a methyl group in the garosamine ring. Complementation of the ΔgenN mutant, carried out by using plasmid pWHU68 containing *genN* under the control of the P*ermE*^∗^ promoter ([Figure S1](#app2){ref-type="sec"}I), restored the production of gentamicin C complex and of various intermediates to wild-type levels ([Figure 2](#fig2){ref-type="fig"}N). Chemical complementation of the ΔgenN mutant by feeding gentamicin A restored production of gentamicin C complex ([Figure S3](#app2){ref-type="sec"}E), confirming that the *genN* gene, like *genD2* and *genS2*, is essential and acts exclusively in the section of the pathway between **3** and **6**, consistent with a specific role in *N*-methylation of the C-3″ amino group.

The remaining step in the conversion of **3** to **4** is the C-methylation of **3** at the C-4″ position ([Figure 1](#fig1){ref-type="fig"}). The gene *genD1* (also known as *gntE* ([@bib42]) or *gtmI* ([@bib21]), previously assigned as an oxidoreductase/methyltransferase ([@bib22]), is a strong candidate to encode this methyltransferase, because it shows significant sequence identity to authentic cobalamin-dependent and radical SAM-dependent methyltransferases ([@bib23]). Accordingly, the *genD1* gene was knocked out by in-frame deletion of an 1,851 bp internal fragment ([Figure S1](#app2){ref-type="sec"}F). In contrast to previous findings based on disruption of the *genD1* gene ([@bib22]), LC-ESI-HRMS analysis showed that fermentation of this mutant produced not only **3** and **7** but also **6** ([Figures 2](#fig2){ref-type="fig"}K and [S2](#app2){ref-type="sec"}D). The most abundant peak was a new species with the mass of **4** but with a different retention time and MS/MS fragmentation pattern ([Figure S2](#app2){ref-type="sec"}E). The appearance of this species (called here gentamicin Ae \[**10**\]) is consistent with GenK-catalyzed methylation of **6** at C-6′ in the absence of its normal gentamicin X2 (**4**) substrate. Complementation of the ΔgenD1 mutant in *trans*, using a plasmid housing *genD1* under a constitutive promoter ([Figure S1](#app2){ref-type="sec"}J), restored wild-type levels of gentamicins ([Figure 2](#fig2){ref-type="fig"}M). Chemical complementation of the ΔgenD1 mutant by feeding **6** did not restore production of gentamicin C complex ([Figure S3](#app2){ref-type="sec"}F), but complementation by feeding with **5** did restore the production of gentamicin C2a, C2, and C1, the products in the "methylated branch" ([Figure S3](#app2){ref-type="sec"}G). This confirmed that the *genD1* gene is essential and acts exclusively in the conversion of **6** to **4**, consistent with a specific role in C-methylation at the C-4″ position. It appears likely that in the disruption mutant previously studied ([@bib22]), there was a deleterious polar effect on the downstream *genS2* gene, which would account for the lack of accumulation of **6** in that study.

Purified Recombinant GenD2, GenS2, and GenN Together Catalyze Successive 3″-Oxidation, Transamination, and *N*-Methylation of Gentamicin A2 to Form Gentamicin A {#sec2.2}
----------------------------------------------------------------------------------------------------------------------------------------------------------------

To obtain direct evidence for the catalytic roles of GenD2, GenS2, and GenN, we turned to in vitro reconstitution experiments, starting with gentamicin A2 (**3**). This substrate was purified from fermentation extracts of the ΔgenS2ΔgenK strain of *M. echinospora* ([Figure 2](#fig2){ref-type="fig"}F), and its identity was confirmed by LC-HRMS. GenD2, GenS2, and GenN were each expressed in *Escherichia coli* as soluble N-His~6~-tagged proteins and purified to near homogeneity ([Figure S4](#app2){ref-type="sec"}A). The molecular weights of the proteins as analyzed by LC-MS were in agreement with the calculated values assuming loss of the N-terminal methionine: 38,533 Da for GenD2 (calculated 38,539 Da); 48,820 Da for GenS2 (calculated 48,826.5 Da); and 37,218 Da for GenN (calculated 37,221.8 Da), respectively. Adventitious *N*-gluconyl modification (+178 Da) ([@bib8]) was also seen with these proteins.

First, the predicted dehydrogenase GenD2 was incubated with **3**, and either NAD^+^ or NADP^+^ as redox cofactor, at 30°C. Samples were analyzed using LC-ESI-HRMS after 10 min, 60 min, 90 min, and overnight incubation. However, no DOA2 (**8**) was detected, even after overnight incubation. Addition of the aminotransferase GenS2, and [l]{.smallcaps}-glutamate as amino donor, also failed to reveal any of the expected DAA2 (**9**). In contrast, when all three enzymes (GenD2, GenS2, and GenN) were present, as well as NAD^+^, [l]{.smallcaps}-glutamate, and SAM (as a methyl donor), essentially complete (\>96%) conversion of **3** ([Figure 3](#fig3){ref-type="fig"}A) to **6** ([Figure 3](#fig3){ref-type="fig"}B) was achieved within 10 min at 30°C. The identity of the product was confirmed by LC-ESI-HRMS analysis, and comparison with authentic **6**: \[M+H\]^+^ *m*/*z* = 469.2498 (−1.28 ppm) and \[M + Na\]^+^ *m*/*z* = 491.2319 (−1.02 ppm) ([Figure 3](#fig3){ref-type="fig"}B). Reactions lacking any one of the three enzymes did not yield any product. These results strongly support the hypothesis that the 3″-modifications on **3** leading to **6** formation are indeed catalyzed by the coupled activities of GenD2, GenS2, and GenN. It is reasonable to speculate that the activities of GenD2 and GenS2 may be inhibited by very low levels of their products and that subsequent 3″-methylation by GenN alleviates this product inhibition.

The Aminoglycosides Kanamycin B and Tobramycin Are Deaminated by GenS2 and GenD2 and Methylated by GenN {#sec2.3}
-------------------------------------------------------------------------------------------------------

To help confirm the respective roles of GenD2 and GenS2, kanamycin B (**11**) and tobramycin (**12**) were used. These aminoglycoside antibiotics are close structural analogs of DAA2 (**9**), and both possess an unmethylated 3″-amino group, so they could be tested as surrogate substrates for 3″-deamination, the reverse of the reaction normally catalyzed by GenS2/GenD2. In these assays, using 2-oxoglutarate as the amino acceptor, LC-ESI-HRMS analysis showed that GenS2 catalyzed low-level deamination of both compounds. The change could be localized to the kanosamine ring, consistent with the production, respectively, of trace amounts of 3″-deamino-3″-oxo-kanamycin B (**13**; \[M + H\]^+^ *m*/*z* 483.2287, \[M + Na\]^+^ *m*/*z* 505.2113) ([Figure S5](#app2){ref-type="sec"}B) and 3″-deamino-3″-oxo-tobramycin (**14**; \[M + H\]^+^ *m*/*z* 467.2342) ([Figure S5](#app2){ref-type="sec"}F). In contrast, in the presence of GenS2 and GenD2 (and either NADH or NADPH) essentially quantitative yields were obtained of, respectively, 3″-deamino-3″-hydroxy-kanamycin B (**15**; \[M + H\]^+^ *m*/*z* 485.2443, \[M + Na\]^+^ *m*/*z* 507.2263) ([Figure S5](#app2){ref-type="sec"}C) and 3″-deamino-3″-hydroxy-tobramycin (**16**; \[M + H\]^+^ *m*/*z* 469.2496, \[M + Na\]^+^ *m*/*z* 491.2314) ([Figure S5](#app2){ref-type="sec"}G).

**11** and **12** were excellent substrates for SAM-dependent methylation by GenN, the reaction being complete after 1 hr at 30°C. For kanamycin B GenN showed *k*~cat~ = 1.93 ± 0.1 s^−1^ and *K*~m~ = 34 ± 3.8 μM (see [Supplemental Experimental Procedures](#app2){ref-type="sec"} for assay details). LC-ESI-HRMS analysis confirmed that methylation in both cases occurred specifically on the kanosamine ring, consistent with the formation, respectively, of 3″-*N*-methyl-kanamycin B (**17**; \[M + H\]^+^ *m*/*z* 498.2761 (−1.81 ppm), \[M + Na\]^+^ *m*/*z* 520.2582 (−1.35 ppm)) ([Figure S5](#app2){ref-type="sec"}D) and 3″-*N*-methyltobramycin (**18**; \[M + H\]^+^ *m*/*z* 482.2814 (−1.45 ppm), \[M + Na\]^+^ *m*/*z* 504.2633 (−1.39 ppm)) ([Figure S5](#app2){ref-type="sec"}H). In contrast, GenN had no effect on **6**, **4**, or **5**, all of which are gentamicin intermediates already methylated at the 3″-N position. These results further confirm the 3″-oxidoreductase activity of GenD2, the 3″-aminotransferase activity of GenS2, and the 3″-*N*-methylation activity of GenN. Purified **15**, when used as substrate for the forward reaction, gave neither detectable **13** with GenS2 alone nor detectable **11** with GenS2 and GenD2 together. However, **15** was smoothly converted by GenS2, GenD2, and GenN into **17**.

The Radical SAM Methyltransferase GenD1 Catalyzes Cobalamin-Dependent Methylation of Gentamicin A to Produce Gentamicin X2 {#sec2.4}
--------------------------------------------------------------------------------------------------------------------------

The putative radical SAM enzyme GenD1 is one of two such intriguing enzymes in the gentamicin pathway, the other being GenK, which catalyzes C-methylation of gentamicin X2 (**4**) at the C-6′ position ([@bib23]). Like GenK, a putative cobalamin-dependent radical SAM C-methyltransferase, and like Sis14 from the gene cluster for the closely related aminoglycoside sisomicin (**19**; [Supplemental Experimental Procedures](#app2){ref-type="sec"}), GenD1 houses a sequence motif (Cx~4~Cx~2~C) highly similar to the conserved Cx~3~Cx~2~C binding site for the \[4Fe-4S\] iron-sulfur cluster found in the radical SAM superfamily ([@bib23]). The iron-sulfur cluster would mediate homolysis of SAM, triggering formation of a gentamicin substrate radical which in turn recruits a methyl group from methylcobalamin. Important preliminary evidence has recently been presented for the in vitro activity of GenK, including the involvement of cobalamin ([@bib23]). GenD1 was accordingly expressed in *E. coli* as a soluble N-His~6~-tagged protein and purified to near homogeneity ([Figure S5](#app2){ref-type="sec"}A). The molecular weight of purified recombinant GenD1 as determined by LC-MS analysis was 77,410 Da, consistent with the calculated mass (77,417.5 Da) of the protein lacking the first methionine. Affinity purification, buffer exchange to remove imidazole, and reconstitution of the iron-sulfur cluster were carried out in an anaerobic chamber to minimize oxidative damage. Purified GenD1 had a brownish color. After reconstitution of the iron-sulfur cluster in GenD1 using ferrous ammonium sulfate and sodium sulfide, the protein solution assumed a gray-black color, as reported for other radical SAM-dependent methyltransferases, and showed a UV-visible absorbance peak centered on 415 nm ([Figure S4](#app2){ref-type="sec"}B) as expected for a protein containing an iron-sulfur cluster ([@bib5; @bib35; @bib23]). The color of the protein faded gradually within hours upon exposure to air.

Freshly purified and reconstituted GenD1 was assayed for its ability to catalyze C-methylation of **6** at the C-4″ position to yield **4**, using conditions previously found successful for GenK ([@bib23]). Incubations (12 hr) were carried out in an anaerobic chamber at 30°C and the reaction mixtures were analyzed by using LC-ESI-HRMS. Reaction mixtures contained commercially available **6** (0.4 mM), SAM (4 mM), dithiothreitol (DTT) (10 mM) and methylcobalamin (1 mM) in 50 mM Tris-HCl buffer (pH 8.0). The reaction was initiated by addition of GenD1 (50 μM). With sodium dithionite (4 mM) as the source of electrons, and with either methyl viologen (MV) or benzyl viologen (BV) (each at 1 mM) present to mediate reductive activation of the iron-sulfur center, only modest (4%--5%) conversion of **6** to a methylated product was seen. However, conversion was increased to 84%--88% when the source of electrons was NADPH (4 mM) ([Figure 4](#fig4){ref-type="fig"}A). The methylated product had a mass consistent with that of **4**: \[M + H\]^+^ *m*/*z* 483.2650 (−2.28 ppm); \[M + Na\]^+^ *m*/*z* 505.2468 (−2.37 ppm). Its MS-MS fragmentation pattern, identical to that of authentic **4** ([Figure 4](#fig4){ref-type="fig"}B), confirmed that the methylation had occurred as expected on the C-4″ position of **6**. As found for GenK, methylcobalamin could be replaced by hydroxocobalamin (14%--18% conversion), suggesting that methylcobalamin can be regenerated by methyltransfer from SAM during catalysis. **4** was not formed in the absence of either cobalamin or viologen. Omission of the reconstitution step, or carrying out assays under aerobic conditions, gave little or no activity. The formation of 5′-deoxyadenosine (**20**, 5′-dAdo**)** as a reaction product was also confirmed by LC-ESI-HRMS (\[M+H\]^+^ *m*/*z* 252.1089 (−1.19 ppm)) ([Figures 4](#fig4){ref-type="fig"}A and [5](#fig5){ref-type="fig"}), suggesting a similar catalytic mechanism to that proposed for GenK, in which a 5′-dAdo radical generated via the reductive cleavage of SAM abstracts a hydrogen from the substrate, leading to the formation of a substrate radical ([@bib23]).

Discussion {#sec3}
==========

The confident application of synthetic biology to reconfigure gene sets and thus redirect the course of an antibiotic biosynthetic pathway requires an excellent understanding of the underlying enzymology. For the biosynthetic pathway to the gentamicin C complex, an established drug to treat life-threatening infections caused by Gram-negative bacteria, even the task of assigning functions to individual gene products involved in the pathway is not trivial because the cluster contains multiple, mutually homologous genes for methyltransferases, oxidoreductases, and aminotransferases with potential for overlapping substrate specificities. There are numerous precedents from other aminoglycoside pathways for enzyme promiscuity or even dual function ([@bib15; @bib6; @bib44; @bib33]). From our analysis of the ΔgenD2, ΔgenS2, and ΔgenN mutants of *M. echinospora* it is clear that GenD2 (dehydrogenase), GenS2 (aminotransferase), and GenN (*N*-methyltransferase) uniquely govern the replacement of the C-3″-hydroxyl group in gentamicin A2 (**3**) by the methylamino group of gentamicin X2 (**4**). No other enzymes in *M. echinospora* were able to take over these roles under the fermentation conditions used, and these enzymes are apparently not required elsewhere in the pathway. The appearance in these mutants of the shunt metabolite gentamicin A2e (**7**) is readily explained by the action of the methyltransferase GenK on the earlier precursors gentamicin A2 (**3**) and gentamicin A (**6**) in the absence of its normal substrate.

The selective production of gentamicin A2 (**3**) from the ΔgenD2ΔgenK mutant provided the substrate to study the recombinant enzymes in vitro. The in vitro work, in turn, confirmed the conclusions from the initial analysis of specific gene knockouts but importantly also revealed that the GenD2/GenS2-catalyzed dehydrogenation/amination only proceeds when the gentamicin A (**6**) product is removed (by GenN-catalyzed methylation) as fast as it is formed. The simplest explanation for this observation is the relief of product inhibition, a neat way to avoid unwanted buildup of reactive pathway intermediates. Indirect confirmation of the likely nature of those intermediates between gentamicin A2 (**3**) and gentamicin A (**6**) could nevertheless be obtained by studying the reactions in reverse, using as substrate analogs of **6** the structurally related aminoglycosides kanamycin B (**11**) and tobramycin (**12**), which each have a free 3″-amino group. GenS2 alone did not catalyze transamination of either substrate but each was efficiently converted into the respective 3″-hydroxy-derivative by the joint action of GenS2 and GenD2. The 3″-hydroxy-kanamycin B (**15**), when used as a substrate for the forward reaction, behaved exactly like gentamicin A2 (**3**): no reaction with GenD2 and GenS2 unless all three enzymes (GenD2, GenS2, and GenN) were present, strongly suggesting that the presence of GenN relieves product inhibition by **13** and **11**.

It has been previously suggested ([@bib22]) that GenD1 catalyzes the *N*-methylation at C-3″ of gentamicin A (**6**), but it is clear from our present work that GenN governs this step. Rather, GenD1 can be confidently assigned, on the basis of both in vivo gene disruption and direct in vitro assay, as the C-methyltransferase that transforms gentamicin A (**6**) into gentamicin X2 (**4**). After GenK ([@bib23]), GenD1 is the second representative of this mechanistically intriguing class of cobalamin-dependent radical SAM methyltransferases to be characterized in the gentamicin pathway. Both these enzymes activate and achieve substitution at unactivated *sp3* C centers. Unlike GenK, which has required refolding from inclusion bodies after heterologous expression ([@bib23]), GenD1 is expressed in *E. coli* as a soluble protein in excellent yield, which should be helpful in future mechanistic study of this enzyme.

Significance {#sec4}
============

**Aminoglycosides, mainly produced by actinobacteria, constitute a vital clinical asset. Gentamicin in particular is of continuing interest because of its remarkable potency in treating systemic Gram-negative infections, and yet because of the significant known toxicity of the gentamicin complex it requires constant and expensive individual monitoring of patients. The perspective of a safer and less expensive gentamicin through administration of a single component, or using a single component for semisynthesis of a novel derivative, is therefore very attractive. The work we report here has used complementary in vivo and in vitro approaches to identify the four key enzymes that lead from the first-formed pseudotrisaccharide to gentamicin X2, the most advanced common precursor of all the components of gentamicin C complex. It has confirmed the activity of soluble recombinant GenD1 as a cobalamin-dependent radical SAM methyltransferase in this pathway, paving the way for detailed mechanistic study of this intriguing enzyme; and, by more closely defining the molecular enzymology of the pathway in *M. echinospora*, has brought closer the goal of assembling a defined set of enzymes to deliver single gentamicin C components.**

Experimental Procedures {#sec5}
=======================

Bacterial Strains and Plasmids, Chemicals, and Culture Conditions {#sec5.1}
-----------------------------------------------------------------

*E. coli* strains NovaBlue and BL21(DE3) (Novagen) were used as cloning and expression hosts, respectively. For routine cloning *E. coli* strains were maintained in 2× TY medium (tryptone 1.6%, yeast extract 1%, NaCl 0.5%) at 37°C with appropriate antibiotic selection at the indicated final concentrations: ampicillin (100 μg/ml), apramycin (50 μg/ml), kanamycin (25 μg/ml), or chloramphenicol (25 μg/ml). For *E. coli* protein expression, Luria-Bertani (LB) medium (1% tryptone, 0.5% yeast extract, 1% NaCl) was used at 37°C with appropriate antibiotic selection at the indicated final concentrations: tetracycline (15 μg/ml) for NovaBlue cells, kanamycin (50 μg/ml) for cells harboring the recombinant pET28a(+) plasmids, and carbenicillin (100 μg/ml) for plasmid pDB1282, containing essential genes for biosynthesis of the iron-sulfur cluster ([@bib45]). Ferrous ammonium sulfate, LB medium, imidazole, NaCl, and Tris base were purchased from Fisher Scientific. Restriction endonucleases, *Pfu* DNA polymerases, and T4 DNA ligase were from Fermentas (Thermo Scientific). Oligonucleotide primers were synthesized by Invitrogen Life Technologies. Gentamicin A (**6**), gentamicin X2 (**4**), and kanamycin B (**11**) were products from Toku-E. G418 used for feeding studies was from Gibco. Amino acids, hydroxocobalamine, methylcobalamine (MeCbl), MV, BV, SAM, sodium dithionite, sodium sulfide, and tobramycin (**12**) were obtained from Sigma-Aldrich.

*M. echinospora* ATCC15835 wild-type and mutants were grown on ATCC 172 medium (glucose 1%, yeast extract 0.5%, soluble starch 2%, N-Z amine 0.5%, CaCO~3~ 0.2%) at 28°C for genomic DNA isolation and cultivation. For aminoglycoside production, the seed culture was shaken at 220 rpm in liquid ATCC 172 medium at 28°C for 2 days and then used to initiate the fermentation culture (5% inoculum) in fermentation medium (Soybean powder 2.0%, peptone 0.1%, glucose 0.3%, (NH~4~)~2~SO~4~ 0.03%, CaCO~3~ 0.3%, KNO~3~ 0.03%, CoCl~2~ 5 ppm) shaken at 220 rpm and at 28°C for 5 days. For feeding experiments, filter-sterilized compounds (150 μg/ml) were added to the fermentation medium before inoculation.

Isolation and Analysis of Gentamicin and Intermediates {#sec5.2}
------------------------------------------------------

The fermentation broth was adjusted to pH 2.0 with concentrated HCl. The cultures were agitated for 2 hr on a laboratory rocker and then centrifuged at 5000 *g* for 10 min at 4°C. Each supernatant was applied to a column of 1.5 g DOWEX 50WX8-200 ion-exchange resin preconditioned with 50 ml acetonitrile followed by 50 ml × 4 distilled-deionized water. The column was washed with 15 ml of water and then aminoglycosides were eluted with 15 ml of 1 M ammonium hydroxide. The eluate was freeze-dried, the residue was dissolved in 1 ml of water, and a sample was subjected to high-performance liquid chromatography-HRMS analysis.

Construction of Gene Disruption Plasmids {#sec5.3}
----------------------------------------

For in-frame deletion, DNA fragments flanking each target gene were amplified from the genomic DNA of *M. echinospora* ATCC15835 using Phusion DNA polymerase (New England Biolabs). The PCR products were each cloned into pUC18, then cut out and cloned together into the *Streptomyces*-*E. coli* shuttle vector pYH7 ([@bib38]) to obtain the following gene disruption plasmids: pWHU6 (for ΔgenD2), pWHU21 (for ΔgenS2), pYH289 (for ΔgenN), and pYH287 (for ΔgenD1). For construction of the ΔgenD2ΔgenK and ΔgenS2ΔgenK double mutants, pWHU1 ([@bib9]) was employed for *genK* in-frame deletion. All plasmids were verified by sequencing.

Construction of Gene Complementation Plasmids {#sec5.4}
---------------------------------------------

Complementation plasmids were prepared by cloning *genD2*, *genS2*, *genN*, *genD1*, and *genK*, respectively, into pWHU77 (a plasmid derived from pIB139 \[[@bib43; @bib4]\] with the apramycin resistance gene replaced by a thiostrepton resistance gene) under the control of the P*ermE^∗^* promoter ([Figure S1](#app2){ref-type="sec"}). The PCR products were inserted into pWHU77 between the NdeI and EcoRI sites to generate pWHU184, pWHU115, pWHU68, pWHU66, and pWHU67. After sequence confirmation, these plasmids were introduced individually into ΔgenD2 (pWHU184), ΔgenS2 (pWHU115), ΔgenN (pWHU68), ΔgenD1 (pWHU66), ΔgenD2ΔgenK (pWHU67), and ΔgenS2ΔgenK (pWHU67) by conjugation. Complemented exconjugants were verified based on thiostrepton resistance and confirmed by PCR ([Figure S1](#app2){ref-type="sec"}).

Targeted In-Frame Gene Deletion {#sec5.5}
-------------------------------

To create individual in-frame deletion mutants of *genD2*, *genS2*, *genN*, and *genD1*, the corresponding plasmid pWHU6, pWHU21, pYH289, and pYH287 was introduced into the wild-type strain by conjugation from *E. coli* ET12567/pUZ8002 ([@bib30]) on ABB medium (soytone 0.5%, soluble starch 0.5%, CaCO~3~ 0.3%, MOPS 0.21%, FeSO~4~ 0.0012%, thiamine-HCl 0.001%, agar 3%) with addition of 10 mM MgCl~2~ solution. After 10 hr incubation at 28°C, the exconjugants were selected with nalidixic acid (12.5 μg/ml) and apramycin (12.5 μg/ml). Exconjugants were transferred onto ABB medium containing nalidixic acid (25 μg/ml) and apramycin (25 μg/ml). To promote a second crossover, these mutants were propagated on A medium (soluble starch 1%, corn steep powder 0.25%, yeast extract 0.3%, CaCO~3~ 0.3%, FeSO~4~ 0.0012%, agar 3% \[pH 7.0\], adjusted with KOH) with addition of 10 mM MgCl~2~ solution. To select the recombinant progeny by their apramycin-sensitive phenotype, single colonies on A plates were patched in parallel onto antibiotic (25 μg/ml apramycin)-containing A medium and antibiotic-free A medium. The desired in-frame deletion mutants were identified by PCR using the checking primers and further confirmed by Southern blot analysis ([Figures S1](#app2){ref-type="sec"}A, S1B, S1E, and S1F). Double in-frame deletion mutants, ΔgenD2ΔgenK and ΔgenS2ΔgenK, were prepared using the same protocol with ΔgenD2 and plasmids pWHU1 ([Figures S1](#app2){ref-type="sec"}C and S1D).

Gene Complementation of the ΔgenD2, ΔgenS2, ΔgenN, ΔgenD1, ΔgenD2ΔgenK, and ΔgenS2ΔgenK Mutants {#sec5.6}
-----------------------------------------------------------------------------------------------

The complementation plasmids were introduced individually into ΔgenD2 (pWHU184), ΔgenS2 (pWHU115), ΔgenN (pWHU68), ΔgenD1 (pWHU66), ΔgenD2ΔgenK (pWHU67), and ΔgenS2ΔgenK (pWHU67) by conjugation. Complemented exconjugants were identified based on thiostrepton resistance and confirmed by PCR ([Figures S1](#app2){ref-type="sec"}G--S1L).

Cloning of *genD1*, *genD2*, *genN*, and *genS2* Genes for Expression in *E. coli* {#sec5.7}
----------------------------------------------------------------------------------

The *genD2*, *genS2*, *genN*, and *genD1* genes were each amplified from the genomic DNA of *M. echinospora* ATCC15835 by PCR using *Pfu* DNA polymerase with 25 cycles of denaturing at 94°C for 1 min, annealing at 60°C for 1 min, and extension at 72°C for 2 min plus a final extension at 72°C for 10 min. The PCR products were digested with appropriate restriction enzymes, purified by gel extraction (Fermentas), and inserted into a pET28a(+) plasmid. The resulting constructs were verified by DNA sequencing.

Overexpression and Purification of Recombinant Proteins {#sec5.8}
-------------------------------------------------------

*E. coli* BL21(DE3) cells bearing the recombinant plasmids were cultured in LB broth containing kanamycin (50 μg/ml) at 37°C until the cell density reached 0.5--1.0 at 600 nm. Overexpression of the proteins was induced by isopropylthiogalactoside (IPTG) (0.1 mM) at 20°C with shaking at 180 rpm overnight. For overexpression of GenD1, *E. coli* BL21(DE3) cells harboring both *genD1* gene in pET28a(+) plasmid and pDB1282 plasmid containing the iron-sulfur cluster biosynthetic genes ([@bib45]) were incubated in 1.5 l of LB broth containing kanamycin and carbenicillin in a 2 l flask at 37°C, 150 rpm until the cell density reached *A*~600~ = 0.8 -- 1.0. The iron-sulfur cluster protein expression was induced with 20 mM [l]{.smallcaps}-(+)-arabinose and the culture incubated for a further 45--60 min. The culture was then cooled to room temperature before addition of 0.2 mM IPTG to induce GenD1 protein expression at 20°C, 150 rpm overnight; 2 mM Fe(II)SO~4~ was also added at this point. Cells were harvested by centrifugation and resuspended in Binding Buffer (0.5 M NaCl, 20 mM Tris-HCl \[pH 7.9\]). The Binding Buffer for GenD1 resuspension was purged with N~2~ for at least 30 min before use. The recombinant protein was released by sonication for 4 min using a 2 s on/6 s off cycle and the recombinant protein in the clarified cell lysate was purified using Co^2+^ or Ni^2+^ ion-charged His-Bind metal chelating resin (Novagen) according to the manufacturer's instructions. Imidazole in the eluted GenD2, GenS2, and GenN solutions was removed by buffer exchange using Amicon Ultra centrifugal filters (Millipore). The purification procedure for GenD1 from the His-Bind purification and onward was carried out in a DAB-10S anaerobic chamber (Saffron Scientific). Imidazole was removed from the purified GenD1 protein solution using a PD10 column (GE Healthcare) with a buffer containing 0.25 M NaCl and 20 mM Tris-HCl (pH 7.9). Anaerobic buffers were prepared outside the anaerobic chamber and autoclaved. Autoclaved buffers were then purged with nitrogen for at least 30 min with stirring before being transferred to the anaerobic chamber, and allowed to stir uncapped at least overnight. Chemical solutions to be stored at −20°C were prepared within the anaerobic chamber and transferred immediately to −20°C after removal from the anaerobic chamber. Chemical solutions freshly prepared on the day of use were dissolved in anaerobic water inside the anaerobic chamber. Tips, tubes, and other consumables were autoclaved and stored in the anaerobic chamber.

The purified proteins were stored at −20°C in a buffer containing 250 mM NaCl, 10 mM Tris-HCl (pH 7.9), and 33% glycerol. The identities of the purified recombinant proteins were confirmed by SDS-PAGE, UV-visible absorbance analysis (Cary 100 Bio UV-visible spectrophotometer), and LC-ESI-MS (ThermoFinnigan). Protein concentrations were determined using Bradford protein dye reagent (Sigma).

Reconstitution of the Iron-Sulfur Cluster in GenD1 {#sec5.9}
--------------------------------------------------

The reconstitution of the iron-sulfur cluster in GenD1 protein was conducted under strictly anaerobic conditions immediately after elution from PD-10 columns. The average temperature in the glove box was 30°C. The protein solution (2.5 ml) was incubated with 5 mM DTT for 15 min followed by addition of 1 mM Fe(II)(NH~4~)~2~(SO~4~)~2~ and 1 mM Na~2~S, both were freshly prepared, yielding a translucent, blackish solution. The solution was left at room temperature for 1 hr, and was then exchanged into a buffer containing 0.25 M NaCl and 20 mM Tris-HCl (pH 7.9) using a PD-10 column. The eluted protein solution remained grayish black, indicating a successful reconstitution. A portion of the reconstituted protein was transferred to a quartz cuvette with a lid and sealed with Parafilm, and was immediately subjected to UV-vis scanning. The reconstituted protein was stored at −80°C, in Eppendorf tubes wrapped in Parafilm, after addition of glycerol to 33% (v/v).

Activity Assays of GenD2, GenS2, and GenN {#sec5.10}
-----------------------------------------

Gentamicin A2 (**3**) purified from the ΔgenS2ΔgenK mutant of *M. echinospora* ATCC15835 (see [Supplemental Experimental Procedures](#app2){ref-type="sec"}, Method S1, for the protocol of purification) was used as a substrate in assays testing the activity of GenD2 as a 3″-dehydrogenase, GenS2 as a 3″-transaminase, and GenN as a 3″-*N*-methyltransferase. A typical reaction (100 μl) contained substrate (400 μM), NAD^+^ or NADP^+^ (2.5 mM), [l]{.smallcaps}-glutamate (1 mM, when GenS2 was present), SAM (2 mM, when GenN was present), and purified enzyme(s) (30 μM each) in Tris-HCl buffer (50 mM, pH 7.5). To test the deamination activity of GenS2 and the subsequent ketoreductase activity of GenD2 (the reverse reactions), kanamycin B (**11**) and tobramycin (**12**) were used as substrates. A typical reaction mixture consisted of substrate (400 μM), NADH or NADPH (2.5 mM), 2-oxoglutarate (1 mM, when GenS2 was present), and purified enzyme(s) (30 μM) in Tris-HCl buffer (50 mM, pH 7.5). Kanamycin and tobramycin were used as substrate analogs to test the putative 3″-*N*-methyltransferase activity of GenN. A typical reaction mixture contained substrate (400 μM), SAM (2 mM), and purified GenN (30 μM) in Tris-HCl buffer (50 mM, pH 7.5). Reaction mixtures were incubated at 30°C and quenched by addition of chloroform (100 μl) followed by vigorous vortexing. Precipitated protein was removed by centrifugation. Ten to twenty microliters of the aqueous supernatant were analyzed by either LC-ESI-MS or LC-ESI-HRMS.

GenD1 Assay {#sec5.11}
-----------

Assays were carried out in an anaerobic chamber (∼30°C) overnight. Standard reaction mixtures (50 μl) contained 1 mM MeCbl, 10 mM DTT, 4 mM SAM, 100 μM purified reconstituted GenD1, 400 μM substrate, 4 mM NADPH, and 1 mM MV in 50 mM Tris-HCl (pH 8). Alternative reducing agents tested were combinations of 4 mM NADPH or Na~2~S~2~O~4~ and 1 mM MV or BV. After incubation, assays were removed from the anaerobic chamber and protein was precipitated by addition of 50 μl of chloroform. The assays were vortexed and then centrifuged at 13,000 rpm for 5 min. Ten to twenty microliters of the aqueous supernatant were analyzed by either LC-ESI-MS or LC-ESI-HRMS.

LC-ESI-MS Analyses {#sec5.12}
------------------

Conditions for LC-ESI-MS analyses were as described in [Supplemental Experimental Procedures](#app2){ref-type="sec"}.
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![The Pathway to Gentamicin X2\
The roles revealed in this study of GenD2, GenS2, GenN, and GenD1 are highlighted in orange. Shunt products of GenK are shown in blue. For details, see the text. A2 (**3**): gentamicin A2; DOA2 (**8**): 3″-dehydro-3″-oxo-gentamicin A2; DAA2 (**9**): 3″-dehydro-3″-amino-gentamicin A2; X2 (**4**): gentamicin X2; A2e (**7**): 6′-methylgentamicin A2; Ae (**6**): 6′-methylgentamicin A. Carbon numbering is shown with the structure of **3**.](gr1){#fig1}

![Production of Gentamicins by *Micromonospora echinospora* Mutants\
LC-ESI-HRMS total ion current traces of (A) gentamicin standard; and of mutant fermentation culture extracts from (B) wild-type; (C) ΔgenD2 mutant; (D) ΔgenS2 mutant; (E) ΔgenD2ΔgenK mutant; (F) ΔgenS2ΔgenK mutant; (G) ΔgenD2::*genD2* mutant; (H) ΔgenS2::*genS2* mutant; (I) ΔgenD2ΔgenK::*genK* mutant; (J) ΔgenS2ΔgenK::*genK* mutant; (K) ΔgenD1 mutant; (L) ΔgenN mutant; (M) ΔgenD1::*genD1* mutant; (N) ΔgenN::*genN* mutant. For the structure of metabolites, see [Figure 1](#fig1){ref-type="fig"}.](gr2){#fig2}

![Enzymatic One-Pot Conversion of Gentamicin A2 to Gentamicin A\
LC-ESI-HRMS selective ion monitoring was carried out on (A) \[M + H\]^+^ (*m*/*z* 456) and \[M + Na\]^+^ (*m*/*z* 478) ions of gentamicin A2 (**3**); (B) \[M + H\]^+^ (*m*/*z* 469) and \[M + Na\]^+^ (*m*/*z* 491) ions of gentamicin A (**6**), produced by the coupled action of GenD2, GenS2, and GenN on gentamicin A2 (**3**). MS/MS fragments from the \[M + H\]^+^ (*m*/*z* 456) and \[M + H\]^+^ (*m*/*z* 469) ions are shown as insets.](gr3){#fig3}

![C-Methylation of Gentamicin A to Gentamicin X2 Catalyzed by GenD1\
LC-ESI-HRMS selective ion monitoring was carried out on (A) \[M + H\]^+^*m*/*z* 483 of the product of GenD1-catalyzed methylation of gentamicin A (**6**); (B) \[M + H\]^+^*m*/*z* 252 of coproduced 5′-dAdo (**20**); (C) MS and MS/MS spectra of gentamicin A (**6**); (D) MS and MS/MS spectra of gentamicin X2 (**4**). Different high-performance liquid chromatography conditions were used for detection of gentamicin X2 (**4**) and 5′-dAdo (**20**), respectively, as described in [Supplemental Experimental Procedures](#app2){ref-type="sec"}. 5′-dAdo, 5′-deoxyadenosine; BV, benzyl viologen; MV, methyl viologen.](gr4){#fig4}

![Production of 5′-Deoxyadenosine during GenD1-Catalyzed Methylation of Gentamicin A\
LC-ESI-HRMS selective ion monitoring and MS/MS fragmentation of 5′-deoxyadenosine (5′-dAdo) (**20**), \[M + H\]^+^*m*/*z* 252.](gr5){#fig5}
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